The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: BAY43-9006 Phase II Study for Renal Cell Carcinoma
Official Title: Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma
Study ID: NCT00661375
Brief Summary: To evaluate efficacy, safety, and pharmacokinetics of BAY 43-9006 in patients with unresectable and/or metastatic renal cell cancer (RCC) who have failed at least one cytokine containing regimen.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Nagoya, Aichi, Japan
, Asahi, Chiba, Japan
, Matsuyama, Ehime, Japan
, Kurume, Fukuoka, Japan
, Isesaski, Gunma, Japan
, Maebashi, Gunma, Japan
, Sapporo, Hokkaido, Japan
, Sapporo, Hokkaido, Japan
, Sapporo, Hokkaido, Japan
, Sapporo, Hokkaido, Japan
, Sunagawa, Hokkaido, Japan
, Tsukuba, Ibaraki, Japan
, Morioka, Iwate, Japan
, Kita, Kagawa, Japan
, Tsu, Mie, Japan
, Natori, Miyagi, Japan
, Sendai, Miyagi, Japan
, Kashihara, Nara, Japan
, Kurashiki, Okayama, Japan
, Osakasayama, Osaka, Japan
, Suita, Osaka, Japan
, Irima-gun, Saitama, Japan
, Tokorozawa, Saitama, Japan
, Hamamatsu, Shizuoka, Japan
, Sunto, Shizuoka, Japan
, Utsunomiya, Tochigi, Japan
, Ube, Yamaguchi, Japan
, Nakakoma, Yamanashi, Japan
, Akita, , Japan
, Chiba, , Japan
, Chiba, , Japan
, Fukuoka, , Japan
, Fukuoka, , Japan
, Kagoshima, , Japan
, Kyoto, , Japan
, Kyoto, , Japan
, Nagasaki, , Japan
, Niigata, , Japan
, Okayama, , Japan
, Osaka, , Japan
, Tokushima, , Japan
, Tokyo, , Japan
, Tokyo, , Japan
, Tokyo, , Japan
, Tokyo, , Japan
, Tokyo, , Japan
, Tokyo, , Japan
, Tokyo, , Japan
, Wakayama, , Japan
, Wakayama, , Japan
, Yamagata, , Japan
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR